Literature DB >> 8831591

Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon.

J N Sengupta1, X Su, G F Gebhart.   

Abstract

BACKGROUND & AIMS: Discomfort and pain are the principal conscious sensations that arise from the viscera, and both are increased in frequency and intensity in patients with a functional bowel disorder. Visceral receptors, perhaps sensitized, may contribute to these altered sensations. The aim of this study was to evaluate the effects of opioid receptor-selective agonists on afferent fibers innervating the colon.
METHODS: Mechanosensitive pelvic nerve afferent fibers were recorded from the decentralized S1 dorsal root in anesthetized rats. The effects of opioid agonists, given intra-arterially, were studied based on the fiber's responses to noxious colorectal distention (CRD) (80 mm Hg, 30 seconds).
RESULTS: A total of 115 distention-sensitive fibers innervating the colon were studied, including 32 that were studied after colonic inflammation with 2.5% acetic acid. Neither mu-(morphine and fentanyl) nor delta- ([D-Pen2, D-Pen5]enkephalin- and SNC-80) opioid receptor agonists affected responses to CRD. In contrast, kappa- (U-50,488 and fedotozine) opioid receptor agonists dose-dependently attenuated responses to CRD. Acetic acid sensitized about half of the fibers studied, but neither the potency nor the efficacy of U-50, 488 or FDZ were changed after colonic inflammation.
CONCLUSIONS: These results suggest a role for peripheral kappa-opioid receptors in the modulation of visceral nociception.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831591     DOI: 10.1016/s0016-5085(96)70064-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

Review 1.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

2.  Opioid-induced bowel dysfunction.

Authors:  Howard Y Chang; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

Review 3.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

4.  The kappa opioid receptor is associated with the perception of visceral pain.

Authors:  D Black; M Trevethick
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 5.  Medical Management of Pain in Chronic Pancreatitis.

Authors:  Vikesh K Singh; Asbjørn M Drewes
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

6.  kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action.

Authors:  S K Joshi; X Su; F Porreca; G F Gebhart
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

7.  Managing pain in inflammatory bowel disease.

Authors:  Michael J Docherty; R Carter W Jones; Mark S Wallace
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

Review 8.  Pharmacological pain management in chronic pancreatitis.

Authors:  Søren S Olesen; Jacob Juel; Carina Graversen; Yuri Kolesnikov; Oliver H G Wilder-Smith; Asbjørn M Drewes
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

9.  Early-in-life bladder inflammation alters U50,488H but not morphine-induced inhibition of visceromotor responses to urinary bladder distension.

Authors:  Amber D Shaffer; Timothy J Ness; Alan Randich
Journal:  Neurosci Lett       Date:  2012-11-29       Impact factor: 3.046

10.  Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.

Authors:  N J Talley; R S Choung; M Camilleri; R A Dierkhising; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2008-03-07       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.